AU2007247292B2 - Use of thymosin alpha1, alone or in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection - Google Patents

Use of thymosin alpha1, alone or in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection Download PDF

Info

Publication number
AU2007247292B2
AU2007247292B2 AU2007247292A AU2007247292A AU2007247292B2 AU 2007247292 B2 AU2007247292 B2 AU 2007247292B2 AU 2007247292 A AU2007247292 A AU 2007247292A AU 2007247292 A AU2007247292 A AU 2007247292A AU 2007247292 B2 AU2007247292 B2 AU 2007247292B2
Authority
AU
Australia
Prior art keywords
thymosin alpha
virus
infection
mice
mcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007247292A
Other languages
English (en)
Other versions
AU2007247292A1 (en
Inventor
Francesco Bistoni
Enrico Garaci
Luigina Romani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2007247292A1 publication Critical patent/AU2007247292A1/en
Application granted granted Critical
Publication of AU2007247292B2 publication Critical patent/AU2007247292B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007247292A 2006-05-02 2007-04-12 Use of thymosin alpha1, alone or in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection Ceased AU2007247292B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06113401 2006-05-02
EP06113401.1 2006-05-02
PCT/EP2007/053574 WO2007128647A1 (en) 2006-05-02 2007-04-12 USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

Publications (2)

Publication Number Publication Date
AU2007247292A1 AU2007247292A1 (en) 2007-11-15
AU2007247292B2 true AU2007247292B2 (en) 2012-04-05

Family

ID=36658736

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007247292A Ceased AU2007247292B2 (en) 2006-05-02 2007-04-12 Use of thymosin alpha1, alone or in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection

Country Status (18)

Country Link
US (1) US8337828B2 (enExample)
EP (1) EP2012816B1 (enExample)
JP (1) JP5441685B2 (enExample)
KR (1) KR101380360B1 (enExample)
CN (1) CN101437535B (enExample)
AU (1) AU2007247292B2 (enExample)
BR (1) BRPI0711136A2 (enExample)
CA (1) CA2649063C (enExample)
CY (1) CY1113277T1 (enExample)
DK (1) DK2012816T3 (enExample)
ES (1) ES2389452T3 (enExample)
HR (1) HRP20120676T1 (enExample)
MX (1) MX2008013872A (enExample)
PL (1) PL2012816T3 (enExample)
PT (1) PT2012816E (enExample)
RS (1) RS52377B (enExample)
SI (1) SI2012816T1 (enExample)
WO (1) WO2007128647A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
EP2675272A4 (en) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US6001799A (en) * 1991-09-13 1999-12-14 Sciclone Pharmaceuticals, Inc. Method of treating hepatitis C in non-responders to interferon treatment
WO2000018417A2 (en) * 1998-09-25 2000-04-06 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
US6106868A (en) * 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
WO2003035111A1 (en) * 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
WO2004094991A2 (en) * 2003-04-23 2004-11-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PT1411971E (pt) 2001-08-03 2006-07-31 Sigma Tau Ind Farmaceuti Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106868A (en) * 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
US6001799A (en) * 1991-09-13 1999-12-14 Sciclone Pharmaceuticals, Inc. Method of treating hepatitis C in non-responders to interferon treatment
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
WO2000018417A2 (en) * 1998-09-25 2000-04-06 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
WO2003035111A1 (en) * 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
WO2004094991A2 (en) * 2003-04-23 2004-11-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Also Published As

Publication number Publication date
DK2012816T3 (da) 2012-09-03
KR101380360B1 (ko) 2014-04-09
BRPI0711136A2 (pt) 2011-08-30
US8337828B2 (en) 2012-12-25
CA2649063C (en) 2014-11-25
WO2007128647A1 (en) 2007-11-15
HRP20120676T1 (hr) 2012-09-30
MX2008013872A (es) 2008-11-14
SI2012816T1 (sl) 2012-09-28
AU2007247292A1 (en) 2007-11-15
US20090275508A1 (en) 2009-11-05
CN101437535A (zh) 2009-05-20
ES2389452T3 (es) 2012-10-26
EP2012816A1 (en) 2009-01-14
JP2009535373A (ja) 2009-10-01
RS52377B (sr) 2012-12-31
HK1128622A1 (en) 2009-11-06
PT2012816E (pt) 2012-08-17
PL2012816T3 (pl) 2012-11-30
KR20090007621A (ko) 2009-01-19
CN101437535B (zh) 2013-01-30
CY1113277T1 (el) 2016-04-13
CA2649063A1 (en) 2007-11-15
JP5441685B2 (ja) 2014-03-12
EP2012816B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
AU2007247292B2 (en) Use of thymosin alpha1, alone or in combination with PTX3 or Ganciclovir, for the treatment of cytomegalovirus infection
US8268304B2 (en) Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
US8357692B2 (en) Methods of treatment of bone degenerative diseases
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
HK1128622B (en) USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION
HK1173983B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases
HK1129301B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired